NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Multiple Technology Appraisal (MTA)

Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for moderate rheumatoid arthritis after conventional DMARDs only have failed (partial review of TA375) [ID2710]

Final stakeholder list of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Companies • AbbVie (adalimumab originator) • Amgen (adalimumab biosimilar) • Biogen (adalimumab biosimilar, etanercept biosimilar, infliximab biosimilar) • Bristol–Myers Squibb (abatacept) • Celltrion Healthcare United Kingdom Limited (infliximab biosimilar) • Fresenius-Kabi (adalimumab biosimilar) • MSD (infliximab originator, golimumab) • Mylan UK (adalimumab biosimilar) • Pfizer (etanercept originator, infliximab biosimilar) • Roche (tocilizumab) • Sandoz (adalimumab biosimilar, etanercept biosimilar, infliximab biosimilar) • UCB (certolizumab pegol) Patient/carer groups • Action on Pain • Arthritis Action • Arthritis and Musculoskeletal Alliance • Back Care • National Rheumatoid Arthritis Society • Pain Concern • Pain UK • South Asian Health Foundation • Specialised Healthcare Alliance • Versus Arthritis	General commentators • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British Biosimilar Association • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare Products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee Comparator companies • Accord Healthcare (methotrexate, hydroxychloroquine sulfate) • Advanz Pharma (methotrexate) • Aspire Pharma Ltd (leflunomide) • Blackrock Pharmaceuticals (hydroxychloroquine sulfate) • Bristol Laboratories Ltd (hydroxychloroquine sulfate) • Cipla (methotrexate) • Hospira UK (methotrexate) • Ipca Laboratories (hydroxychloroquine sulfate)

© National Institute for Health and Care Excellence 2020. All rights reserved.

Professional groups

- British Geriatrics Society
- British Institute of Musculoskeletal Medicine
- British Orthopaedic Association
- British Pain Society
- British Society for Rheumatology
- British Society of Rehabilitation Medicine
- Chartered Society of Physiotherapy
- Physiotherapy Pain Association
- Primary Care Rheumatology Society
- Rheumatoid Arthritis Surgical Society
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Occupational Therapists
- Royal College of Pathologists
- Royal College of Physicians
- Royal College of Radiologists
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Society and College of Radiographers
- UK Clinical Pharmacy Association

Others

- Department of Health and Social Care
- NHS Durham Dales, Easington and Sedgefield CCG
- NHS England
- NHS South Tyneside CCG
- Welsh Government
- Medac (methotrexate, leflunomide)
- Mylan (leflunomide)
- Nordic Pharma Limited (methotrexate)
- Orion Pharma (methotrexate)
- Pfizer (methotrexate, sulfasalazine)
- Rosemont (methotrexate, sulfasalazine)
- Sandoz (methotrexate, leflunomide)
- Sanofi (leflunomide)
- Therakind Limited (methotrexate)
- Tillomed Laboratories (leflunomide)
- Zentiva (hydroxychloroquine sulfate)

Relevant research groups

- Bone Research Society
- Chronic Pain Policy Coalition
- Cochrane Musculoskeletal Group
- Cochrane Skin Group
- Genomics England
- MRC Clinical Trials Unit
- National Institute for Health Research
- Orthopaedic Research UK
- Pain Relief Foundation
- Society of Back Pain Research

Associated Public Health Groups

- Public Health England
- Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

© National Institute for Health and Care Excellence 2020. All rights reserved.

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to prepare a submission dossier, can respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Document (FAD).

All non- company consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, and the British National Formulary.

All non-company organisations can nominate clinical or patient experts to present their personal views to the Appraisal Committee.

© National Institute for Health and Care Excellence 2020. All rights reserved.